Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)
Retrospective trial showed Overall Response Rate (ORR) improved to 86% at the end of the second 12-month period (Year 2) compared to 72% observed at the end of the initial 12-month Phase 1/2 trial (Year 1); the Complete Response (CR) rate improved to 50% for Year 2 from 28% for Year 1...
Related Questions
How will the improved ORR and CR rates for INO-3107 affect INO's valuation and target price?
What are the expectations for FDA or other regulatory filings based on these Phase 1/2 results?
How does INO-3107's efficacy compare to existing treatments for Recurrent Respiratory Papillomatosis and to competitors' pipelines?
Will the long-term surgery reduction data expand the addressable market for INO-3107?
What is the anticipated timeline for moving from Phase 1/2 to Phase 3 trials, and how might that impact the stock?
How might the trial results influence partnership or licensing opportunities for INO?
What are the potential risks or uncertainties surrounding the durability of the response beyond the 2‑year data?
How could the positive data affect analyst sentiment and coverage upgrades or downgrades?
What is the expected impact on INO's cash burn and financing needs given the need for larger pivotal trials?
Are there any upcoming conference presentations or investor calls where the data will be further discussed?